Re: Response of a KIT-positive extra-abdominal fibromatosis to imatinib mesylate and KIT genetic analysis.
Tamborini
Elena
E
Negri
Tiziana
T
Miselli
Francesca
F
Lagonigro
M Stefania
MS
Pricl
Sabrina
S
Pilotti
Silvana
S
D000409:Alanine; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D014408:Biomarkers, Tumor / Q000235:genetics; D003545:Cysteine; D005350:Fibroma / Q000188:drug therapy* / Q000235:genetics; D006801:Humans; D000068877:Imatinib Mesylate; D007930:Leucine; D008715:Methionine; D016296:Mutagenesis; D009154:Mutation; D010879:Piperazines / Q000627:therapeutic use*; D011110:Polymorphism, Genetic; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D014408:Biomarkers, Tumor; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D008715:Methionine; D011505:Protein-Tyrosine Kinases; D019009:Proto-Oncogene Proteins c-kit; D007930:Leucine; D003545:Cysteine; D000409:Alanine